CAMP4 Therapeutics Corporation, a biotechnology firm, was established in 2015 by Richard A. Young and Leonard Zon. Based in Cambridge, Massachusetts, its ...
Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer
Est. EPS $-0.17 · Revenue $2.11M · 3 analysts
Est. EPS $-0.16 · Revenue $2.11M · 3 analysts
Est. EPS $-1.10 · Revenue $7.28M · 5 analysts
Est. EPS $-0.15 · Revenue $2.42M · 1 analysts
| Metric | Latest | YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength. | QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes. |
|---|---|---|---|
| RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three). | $3.5M | +436.5% | +37.5% |
| Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day. | $-80.4M | -55.2% | -82.9% |
| Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials. | +53.1% | -46.9% | +67.2% |
| Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on). | -1488.3% | +81.7% | +25.5% |
| Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales. | -2298.5% | +71.1% | -33.0% |
| Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock. | $-29.8M | +35.2% | -16.7% |
| FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine. | -852.8% | +87.9% | +15.1% |
| Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe. | 4.1% | -69.8% | -5084.5% |
| Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking. | 7.35x | +6.3% | -23.5% |
| Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground. | $117.8M | +50.4% | -11.4% |
| Metric | Annual (A vs E) | Annual Surprise | Quarter (A vs E) | Quarter Surprise |
|---|---|---|---|---|
| EPS Surprise | -2.65 vs -2.12 | -24.7% | -0.58 vs -0.17 | -241.8% |
| Revenue Surprise | $3.5M vs $3.6M | -1.6% | $1.8M vs $2.1M | -15.6% |
| Date | Executive | Title | Security | Side | Shares | Price |
|---|---|---|---|---|---|---|
| Aug 31, 2026 | Gold Kelly | officer: Chief Financial Officer | Common Stock | A | 10,000 | $3.96 |
| Aug 27, 2026 | Schwab Andrew J. | director | Common Stock | D | 400,000 | $4.04 |
| Aug 24, 2026 | Schwab Andrew J. | director | Common Stock | D | 10 | $4.50 |
| Aug 21, 2026 | Schwab Andrew J. | director | Common Stock | D | 32,018 | $4.50 |
| Aug 20, 2026 | Schwab Andrew J. | director | Common Stock | D | 114,700 | $4.54 |
| Name | Title | Compensation | Gender | Year Born | Status |
|---|---|---|---|---|---|
Joshua Mandel-Brehm | Chief Executive Officer, President & Director | USD 896,250 | Male | 1983 | Active |
Kelly Gold | Chief Financial Officer | USD 734,691 | Female | 1977 | Active |
Yuri Maricich | Chief Medical Officer | USD 702,000 | — | 1981 | Active |
Richard A. Young | Founder & Independent Director | USD 146,556 | — | 1954 | Active |
Leonard I. Zon | Founder & Chairman of Scientific Advisory Board | — | — | — | Active |
Caleb Moore | Chief Business Operations Officer | — | Male | — | Active |
Michelle Gates | Senior Vice President & Chief People Officer | — | Female | — | Active |
Alla Sigova | Senior Vice President of Platform | — | Female | — | Active |
Daniel Tardiff | Chief Scientific Officer | — | — | 1980 | Active |
Satya Kuchimanchi | Senior Vice President of Technical Operations | — | — | — | Active |
CAMP4 Therapeutics Corporation (CAMP) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.24. This compares to a loss of $0.62 per share a year ago.
Secured regulatory clearance in two jurisdictions to initiate first-in-human Phase 1/2 clinical trial of CMP-002 in patients with SYNGAP-1 related disorder; trial initiation anticipated in the fourth quarter of this year.
CAMP4 Therapeutics received regulatory clearance in Australia and Argentina to begin a Phase 1/2 trial of CMP-002, its experimental ASO therapy for SYNGAP1-related disorders. The trial will enroll at least 30 children ages 2 to 18 and use a double-blind, placebo-controlled design, with placebo recipients able to transition to the treatment if early results are positive.
New woodsy-themed family area will feature nine attractions, including the Midwest's longest, tallest and fastest suspended family coaster as part of a multi-year transformation MEDIA KIT: Photo, Video & Logos GURNEE, Ill., Aug. 6, 2026 /PRNewswire/ -- Six Flags Great America, the premier theme park destination in the Chicagoland area, today announced plans to debut Camp Timber Trail, an all-new family adventure opening in 2027.
Proceeds of $50.1 million will be used to support the Company's advancement of CMP-002 for the treatment of SYNGAP1-related disorder Proceeds of $50.1 million will be used to support the Company's advancement of CMP-002 for the treatment of SYNGAP1-related disorder
